BACKGROUND AND AIMS: With the advent of regenerative therapy, there is renewed interest in the use of bone marrow as a source of adult stem and progenitor cells, including cell subsets prepared by immunomagnetic selection. Cell selection must be rapid, efficient and performed according to current good manufacturing practices. In this report we present a methodology for intra-operative preparation of CD34(+) selected autologous bone marrow for autologous use in patients receiving coronary artery bypass grafts or left ventricular assist devices. METHODS AND RESULTS: We developed a rapid erythrocyte depletion method using hydroxyethyl starch and low-speed centrifugation to prepare large-scale (mean 359 mL) bone marrow aspirates for separation on a Baxter Isolex 300i immunomagnetic cell separation device. CD34 recovery after erythrocyte depletion was 68.3 ± 20.2%, with an average depletion of 91.2 ± 2.8% and an average CD34 content of 0.58 ± 0.27%. After separation, CD34 purity was 64.1 ± 17.2%, with 44.3 ± 26.1% recovery and an average dose of 5.0 ± 2.7 × 10(6) CD34(+) cells/product. In uncomplicated cases CD34-enriched cellular products could be accessioned, prepared, tested for release and administered within 6 h. Further analysis of CD34(+) bone marrow cells revealed a significant proportion of CD45(-) CD34(+) cells. CONCLUSIONS: Intra-operative immunomagnetic separation of CD34-enriched bone marrow is feasible using rapid low-speed Hetastarch sedimentation for erythrocyte depletion. The resulting CD34-enriched product contains CD45(-) cells that may represent non-hematopoietic or very early hematopoietic stem cells that participate in tissue regeneration.
BACKGROUND AND AIMS: With the advent of regenerative therapy, there is renewed interest in the use of bone marrow as a source of adult stem and progenitor cells, including cell subsets prepared by immunomagnetic selection. Cell selection must be rapid, efficient and performed according to current good manufacturing practices. In this report we present a methodology for intra-operative preparation of CD34(+) selected autologous bone marrow for autologous use in patients receiving coronary artery bypass grafts or left ventricular assist devices. METHODS AND RESULTS: We developed a rapid erythrocyte depletion method using hydroxyethyl starch and low-speed centrifugation to prepare large-scale (mean 359 mL) bone marrow aspirates for separation on a Baxter Isolex 300i immunomagnetic cell separation device. CD34 recovery after erythrocyte depletion was 68.3 ± 20.2%, with an average depletion of 91.2 ± 2.8% and an average CD34 content of 0.58 ± 0.27%. After separation, CD34 purity was 64.1 ± 17.2%, with 44.3 ± 26.1% recovery and an average dose of 5.0 ± 2.7 × 10(6) CD34(+) cells/product. In uncomplicated cases CD34-enriched cellular products could be accessioned, prepared, tested for release and administered within 6 h. Further analysis of CD34(+) bone marrow cells revealed a significant proportion of CD45(-) CD34(+) cells. CONCLUSIONS: Intra-operative immunomagnetic separation of CD34-enriched bone marrow is feasible using rapid low-speed Hetastarch sedimentation for erythrocyte depletion. The resulting CD34-enriched product contains CD45(-) cells that may represent non-hematopoietic or very early hematopoietic stem cells that participate in tissue regeneration.
Authors: A D Donnenberg; E K Koch; D L Griffin; H M Stanczak; J E Kiss; T M Carlos; D M Buchbarker; A M Yeager Journal: Cytotherapy Date: 2002 Impact factor: 5.414
Authors: Vera S Donnenberg; Albert D Donnenberg; Ludovic Zimmerlin; Rodney J Landreneau; Rohit Bhargava; Ryan A Wetzel; Per Basse; Adam M Brufsky Journal: Cytometry B Clin Cytom Date: 2010-04-30 Impact factor: 3.058
Authors: N C Gorin; M Lopez; J P Laporte; P Quittet; S Lesage; F Lemoine; R J Berenson; F Isnard; M Grande; J Stachowiak Journal: Blood Date: 1995-03-15 Impact factor: 22.113
Authors: J E Wagner; G W Santos; S J Noga; S D Rowley; J Davis; G B Vogelsang; E R Farmer; B A Zehnbauer; R Saral; A D Donnenberg Journal: Blood Date: 1990-03-15 Impact factor: 22.113
Authors: R J Berenson; W I Bensinger; R S Hill; R G Andrews; J Garcia-Lopez; D F Kalamasz; B J Still; G Spitzer; C D Buckner; I D Bernstein Journal: Blood Date: 1991-04-15 Impact factor: 22.113
Authors: Douglas W Losordo; Richard A Schatz; Christopher J White; James E Udelson; Vimal Veereshwarayya; Michelle Durgin; Kian Keong Poh; Robert Weinstein; Marianne Kearney; Muqtada Chaudhry; Aaron Burg; Liz Eaton; Lindsay Heyd; Tina Thorne; Leon Shturman; Peter Hoffmeister; Ken Story; Victor Zak; Douglas Dowling; Jay H Traverse; Rachel E Olson; Janice Flanagan; Donata Sodano; Toshinori Murayama; Atsuhiko Kawamoto; Kengo Fukushima Kusano; Jill Wollins; Frederick Welt; Pinak Shah; Peter Soukas; Takayuki Asahara; Timothy D Henry Journal: Circulation Date: 2007-06-11 Impact factor: 29.690
Authors: Vijay S Gorantla; Stefan Schneeberger; Linda R Moore; Vera S Donnenberg; Ludovic Zimmerlin; W P Andrew Lee; Albert D Donnenberg Journal: Cytotherapy Date: 2011-09-12 Impact factor: 5.414
Authors: Kai-Hsin Chang; Sarah E Smith; Timothy Sullivan; Kai Chen; Qianhe Zhou; Jason A West; Mei Liu; Yingchun Liu; Benjamin F Vieira; Chao Sun; Vu P Hong; Mingxuan Zhang; Xiao Yang; Andreas Reik; Fyodor D Urnov; Edward J Rebar; Michael C Holmes; Olivier Danos; Haiyan Jiang; Siyuan Tan Journal: Mol Ther Methods Clin Dev Date: 2017-01-11 Impact factor: 6.698